Clinical Trial

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2016-04-07; most recent amendment 2026-07-13.
Status change: Recruiting → Active, Not Recruiting 2019-10-09
Status change: Not Yet Recruiting → Recruiting 2016-04-12
Trial Details
NCT Number NCT02736656
Lead Sponsor Supernus Pharmaceuticals, Inc.
Conditions Attention-Deficit/Hyperactivity Disorder
Enrollment 1,400 participants
Start Date 2016-02-02
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-15